GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

GlycoNex 4168.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

21.00

+5.26%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About GlycoNex

Its shares trade on Taipei Exchange under the ticker 4168.TWO. It has been listed since 16 December 2011. In the fiscal year to 31 December 2025, it reported revenue of TWD 37.9m and a net loss of TWD 235.2m. At that date it held total assets of TWD 1.55bn and shareholders' equity of TWD 982.3m.

GlycoNex, Inc. engages in the anti-cancer monoclonal antibody development. The company is headquartered in Taipei, New Taipei. The company went IPO on 2011-12-16. The firm is mainly involved in the development of anti-cancer monoclonal antibody new drugs and bio-similar drugs, as well as the licensing of monoclonal antibody targets and carbohydrate antigen and protein drug related services. The firm distributes its products in domestic market and to overseas markets, such as the rest areas of Asia.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
16 Dec 2011

Leadership

Pay as last reported

  • Dongxuan ZhangChairman of the Board, since 2001
  • Meijun YangGeneral Manager, since 2011
  • Yaohua LuDeputy General Manager, Corporate Governance Officer, since 2023
  • Difen WuHead of Finance and Accounting
  • Gaozhong CaiDirector
  • Caiqing HongDirector
  • Liangyin LiuDirector
  • Xiu'e SuDirector
  • Ms. Lingjun CaiIndependent Director
  • Jiongsen LinIndependent Director
  • Zongzheng WuIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • GlycoNex Inc develops anti-cancer monoclonal antibodies in Taipei, Taiwan.
  • The company focuses on bio-similar drugs and carbohydrate antigen services.
  • GlycoNex distributes products in domestic and Asian markets effectively.

Weaknesses

  • GlycoNex Inc's IPO was in 2011, limiting recent capital access.
  • The firm's product development is concentrated in anti-cancer monoclonal antibodies.
  • GlycoNex relies on domestic and Asian markets for distribution.

Opportunities

  • GlycoNex can expand into new markets beyond Asia for monoclonal antibody drugs.
  • The company can leverage bio-similar drug development for cost-effective solutions.
  • GlycoNex may grow by licensing antibody targets and protein drug services.

Threats

  • GlycoNex faces competition from established biotechnology firms in Asia.
  • Regulatory challenges in anti-cancer drug development could delay approvals.
  • Market saturation in monoclonal antibody services may reduce profit margins.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.